Generic Name and Formulations:
Alcaftadine 0.25%; oph soln; contains benzalkonium chloride.
Indications for LASTACAFT:
Prevention of ocular itching associated with allergic conjunctivitis.
Adults and Children:
<2yrs: not established. ≥2yrs: 1 drop in each eye once daily.
Contact lenses (remove; may reinsert 10 mins after administration, if eye is not red). Pregnancy (Cat.B). Nursing mothers.
H1 histamine receptor antagonist.
Ocular effects (eg, irritation, burning/stinging, redness, pruritus), nasopharyngitis, headache.
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Concurrent Risk Factors and Microvascular Complications in Type 1 Diabetes
- Higher Risk for Meningioma Linked to GH Treatment, Radiotherapy During Childhood
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Comparing Antidiabetic Drug Classes for Risk of Heart Failure
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- Ivacaftor Improves Insulin Secretion in Children With Cystic Fibrosis
- Genetic Testing Recommended for Familial Hypercholesterolemia
- Behavioral Weight Loss Interventions May Prevent Obesity
- Disaster Preparedness 101: Physician Resources for Patients
- Assessing the Environmental Impact of the Healthcare Industry